| Methods |
Location: USA, randomised, non‐blinded trial
Participants were randomised to receive either azithromycin or amoxycillin/clavulanate in those aged 6 months to 5 years, and erythromycin in children aged older than 5 years. Participants were evaluated at enrolment and again at 2 to 3 days and 10 to 37 days after the treatment started |
| Participants |
88 participants with community‐acquired pneumonia at the Children's Medical Center of Dallas aged 6 months to 16 years were enrolled. Participants aged 6 months to 5 years: azithromycin group N = 39, amoxy‐clavulanic acid group N = 49 |
| Interventions |
1. Azithromycin oral suspension 10 mg/kg (maximum 500 mg) once on day 1, followed by 5 mg/kg (maximum 250 mg) once daily for 4 days
2. Conventional therapy, 3 times daily for 10 days (amoxycillin/clavulanic acid 40 mg/kg/day for participants aged 6 months to 5 years, and erythromycin estolate 40 mg/kg/day for children aged 5 to 16 years) |
| Outcomes |
Cure
Improvement
Failure
Adverse events |
| Notes |
— |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No information about how the list of randomised therapy assignments was generated |
| Allocation concealment (selection bias) |
Unclear risk |
No information was available |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
Unblinded treatment |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
147 were randomised, 69 to the azithromycin group and 78 to the amoxycillin group. All were analysed |
| Selective reporting (reporting bias) |
Unclear risk |
The study protocol is not available |
| Other bias |
Low risk |
Baseline characteristics were comparable between the 2 treatment groups |
